AiCuris Anti-infective Cures AG

General information

AiCuris Anti-infective Cures AG
Friedrich-Ebert-Str. 475
Building 302
42117 Wuppertal, North Rhine-Westphalia
Germany

Contact person: Holger Zimmermann, Chief Executive Officer
Company main phone: +49 (202) 317630
Company main fax: +49 (202) 317631177
Website: https://www.aicuris.com

Year founded:	2006
Source of foundation:	Spin-off from company
Name of foundation source:	Bayer Infection Research

Corporate description / mission:
AiCuris is a pharmaceutical company focused on the discovery, research and development of antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.The company’s first product, Letermovir (Prevymis®) is a therapy for human cytomegalovirus (HCMV) infections.

State of ownership: Private / independent
Headquarters: Yes

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Anti-infectives
Proteins
Small molecules

Primary therapeutic areas:

Infectious and parasitic diseases / infectiology / parasitology

Business model:

In-licensing
Out-licensing
R&D

Customer segments:

Large biotech & big pharma
Small biotech

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	4
Phase I:	2
Phase III:	3
On the market:	1

Description of products:
Products:
Prevymis® / Letermovir (AIC246)
Pritelivir (AIC316)
Artilysins®, etc.

Collaborations & Clients

Partnering strategy / collaborations:
Merck & Co.
Royalty Pharma
Hybridize Therapeutics
Lysando